Meet Proteona at the 18th International Myeloma Workshop
Innovative AI-driven genomic and proteomic analysis platform for improving cell therapy and immuno-oncology
Proteona will attend the 18th International Myeloma Workshop (IMW) 2021, taking place on September 8-11. It will be a hybrid event with in-person meetings in Vienna, Austria and virtual meetings online.
IMW is one of the most important meetings internationally on multiple myeloma scientific research, clinical management, and innovation. The 2021 program will cover topics from molecular profiling of myeloma, updates on treatment approaches, and emerging techniques including single-cell analysis.
Meet us to discuss how single-cell multi-omics can help in managing multiple myeloma. Book an in-person or a conference call with us now!
For media queries, please contact:
Dr. Andreas Schmidt
Proteona is a precision medicine company in Singapore, Germany, and the US that is pioneering the use of single cell multi-omics to improve clinical outcomes in cancer. Using a combination of innovative single cell assays and AI-assisted bioinformatics, Proteona enables pharmaceutical companies, biotech partners, and clinicians to integrate single cell level precision into their clinical projects. Proteona continues to develop comprehensive, disease-specific single cell databases combining gene expression, protein expression, and mutation information derived from each individual cells as well as drug response data for each sample. Proteona has been selected as a “One to Watch” by Nature Research Spinoff Award and a Winner of Falling Walls Ventures Breakthrough of the Year 2020. Proteona is a spin-off from the National University of Singapore (NUS) and the Agency for Science, Technology and Research (A*STAR).